Iconography : Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE)
2018
Keywords:
-
Correction
-
Cite
-
Save
0
References
0
Citations
NaN
KQI